MedTrace Logo

Study of Antiinflammatory Effects of Detralex (Daflon)

NCT01654016 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2019-11-01

No results posted yet for this study

Summary

Aim of the study:

To investigate if there is a differences in expression of inflammatory markers in venous wall and blood among patients treated with Detralex and those not treated with Detralex (control group).

Conditions

  • Chronic Venous Insufficiency

Interventions

DRUG

Detralex

Detralex 500 mg twice daily for three month prior to surgery

Sponsors & Collaborators

  • Servier

    collaborator INDUSTRY

  • University Hospital Dubrava

    lead OTHER

Principal Investigators

  • Marko Ajduk, PhD · University Hospital Dubrava

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2019-05-31
Completion
2019-09-30

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654016 on ClinicalTrials.gov